Literature DB >> 14668640

Severe bleeding in idiopathic thrombocytopenic purpura.

Paula Bolton-Maggs1.   

Abstract

Immune thrombocytopenia in childhood is usually an acute self-limiting disorder and despite very low platelet counts is rarely complicated by serious bleeding. Several surveys indicate that only 5% or fewer children experience serious bleeding, most commonly from the nose or gastrointestinal tract. Such children need urgent measures to control bleeding, both transfusion where necessary and pharmacotherapy to raise the platelet count. Not infrequently the response of the count is less than optimal. While intracranial hemorrhage is the most feared and serious complication, it is rare, occurring in about 0.3% of cases, and if treated promptly usually has a good outcome. Treatment prior to intracranial hemorrhage does not necessarily prevent it, and it may occur after many months of otherwise clinically mild disease. The relative risk increases with the length of time a child has a very low platelet count. An international registry will help to collect more information about these important cases. Menstrual bleeding can cause severe problems for adolescents and may need a multidisciplinary approach with hormonal manipulation of the menstrual cycle.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14668640     DOI: 10.1097/00043426-200312001-00011

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  9 in total

Review 1.  Childhood immune thrombocytopenia: Clinical presentation and management.

Authors:  Mohamed El Faki Osman
Journal:  Sudan J Paediatr       Date:  2012

2.  Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia.

Authors:  B Psaila; J B Bussel; A L Frelinger; B Babula; M D Linden; Y Li; M R Barnard; C Tate; E J Feldman; A D Michelson
Journal:  J Thromb Haemost       Date:  2011-11       Impact factor: 5.824

3.  Use of Recombinant Factor VIIa in a Pediatric Patient With Initial Presentation of Refractory Acute Immune Thrombocytopenic Purpura and Severe Bleeding.

Authors:  Reut Gurion; Anita Siu; Aaron R Weiss; Margaret Masterson
Journal:  J Pediatr Pharmacol Ther       Date:  2012-07

4.  Chronic immune thrombocytopenia in a child responding only to thrombopoietin receptor agonist.

Authors:  Mohamed E Osman
Journal:  Sudan J Paediatr       Date:  2012

5.  Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura.

Authors:  Cindy E Neunert; George R Buchanan; Paul Imbach; Paula H B Bolton-Maggs; Carolyn M Bennett; Ellis J Neufeld; Sara K Vesely; Leah Adix; Victor S Blanchette; Thomas Kühne
Journal:  Blood       Date:  2008-08-12       Impact factor: 22.113

6.  Eltrombopag For Immune Thrombocytopenic Children in a Single Region.

Authors:  Göksel Leblebisatan; Yurdanur Kilinc; Metin Cil; İlgen Sasmaz; Ayse Ozkan
Journal:  Indian J Hematol Blood Transfus       Date:  2018-02-05       Impact factor: 0.900

7.  Risk Factors and Psychological Analysis of Chronic Immune Thrombocytopenia in Children.

Authors:  Ying Sun; Sili Long; Wenjun Liu
Journal:  Int J Gen Med       Date:  2020-12-30

8.  Clinical course and prognostic factors of childhood immune thrombocytopenia: single center experience of 10 years.

Authors:  Jae Yeob Jung; A Rum O; Je Keong Kim; Meerim Park
Journal:  Korean J Pediatr       Date:  2016-08-24

9.  Efficacy and Safety of IQYMUNE®, a Ten Percent Intravenous Immunoglobulin in Adult Patients With Chronic, Primary Immune Thrombocytopenia.

Authors:  Francesco Rodeghiero; Dariusz Woszczyk; Borhane Slama; Anait Melikyan; Jean-Francois Viallard; Rabye Ouaja; Ousmane Alfa Cisse; Alain Sadoun; Abdulgabar Salama
Journal:  J Hematol       Date:  2018-09-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.